February 2, 2026 PK of budigalimab was approximately dosage proportional and sustained >99% peripheral PD1 receptor saturation was observed by 2hours postdosing, across dosages
January 3, 2023 Finally, we suggest that the combined usage of miR-modulating compounds with epigenetic medications might provide a novel avenue to enhance the clinical efficacy of existing anti-cancer therapies in CTCL
June 29, 2022 The enhanced obinutuzumab-triggered response, needlessly to say, was seen in conventional NK cell populations also
January 1, 2022 cCg As depicted in c, NSG mice (d, e), and NOD-mice (f, g) were orthotopically implanted with E0771-Luc or E0771-Luc-cells